Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648438 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02648438 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT02648438, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two different dry powder inhalers (DPIs) and a pressurized meter-dose inhaler (pMDI)
Interventions
- DRUG AZD7594 Solution for infusion (150 μg intravenous formulation)
- DRUG AZD7594 Oral suspension (1200 μg oral formulation)
- DRUG AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
- DRUG AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
- DRUG AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-01-12 |
| Est. Completion | 2016-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648438
The ClinicalTrials.gov registry entry for NCT02648438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AZD7594 Solution for infusion (150 μg intravenous formulation) is the first listed.
NCT02648438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02648438 about?
NCT02648438 is a clinical study titled "A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects". This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two different dry powder inhalers (DPIs) and a pressurized meter-dose inhaler ...
What is the current status of trial NCT02648438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-01-12. Estimated completion is 2016-06-01.
What interventions are being tested in trial NCT02648438?
The interventions under investigation include: AZD7594 Solution for infusion (150 μg intravenous formulation) (DRUG), AZD7594 Oral suspension (1200 μg oral formulation) (DRUG), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler) (DRUG), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) (DRUG), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI (DRUG).
Who is sponsoring clinical trial NCT02648438?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.